logo
SquareX secures US$20 million to transform browser security

SquareX secures US$20 million to transform browser security

Business Mayor27-04-2025

SquareX has announced the close of its Series A funding round, raising US$20 million. The investment was led by SYN Ventures, a venture capital firm specialising in cybersecurity, with continued support from Peak XV Partners, formerly known as Sequoia Capital SEA.
The Singapore-based company has pioneered Browser Detection and Response (BDR), a solution that strengthens security directly within the browser. Its approach eliminates the need for businesses to adopt entirely new enterprise browsers, which can often disrupt user experience and productivity. Instead, SquareX offers a simple extension that turns any browser into a secure, enterprise-grade tool.
Vivek Ramachandran, CEO of SquareX, said, 'The browser is the new endpoint, yet it remains a major blind spot for most organisations. Existing solutions often force a trade-off between security and usability. We built SquareX to eliminate this compromise in browser security, offering robust protection that works with the browsers users are already familiar with. This Series A funding, led by the team at SYN Ventures, validates our vision of everyone being able to be online without fear.'
As browsers have increasingly become primary targets for cyberattacks, the need for better security solutions has grown urgent. Traditional security tools often lack the ability to monitor threats at the browser level, and adopting proprietary enterprise browsers can create friction in daily workflows.
SquareX addresses these challenges with its BDR extension. It allows enterprises to detect and manage threats such as malicious extensions, phishing attempts, data leakage through generative AI, and insider threats. By operating within the native browser environment, SquareX significantly reduces the attack surface without compromising usability or requiring complex change management.
Jay Leek, Managing Partner and Founder of SYN Ventures, commented, 'SquareX is tackling one of the most significant and underserved areas in cybersecurity today. The browser is ground zero for countless attacks, and the team at SquareX has developed an elegant and powerful solution that provides critical visibility and control where it's needed most – directly within the native browser experience.'
Peak XV Partners, which first invested during SquareX's seed stage, has expressed confidence in the company's progress and direction.
'Having partnered with SquareX since their seed stage, we've been impressed by their vision and execution in tackling browser security challenges. We are excited to partner with them again as they demonstrate strong results in delivering much-needed cybersecurity capabilities to enterprise customers,' said Shailendra Singh, Managing Director at Peak XV.
SquareX's innovative approach aims to reshape how enterprises think about browser security, offering a way to protect users without disrupting their preferred digital workflows.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EngageLab Unveils Intelligent, End-to-End Email Solution to Empower Brand Growth
EngageLab Unveils Intelligent, End-to-End Email Solution to Empower Brand Growth

Yahoo

timean hour ago

  • Yahoo

EngageLab Unveils Intelligent, End-to-End Email Solution to Empower Brand Growth

SINGAPORE, June 10, 2025 (GLOBE NEWSWIRE) -- EngageLab, a leading global provider of intelligent marketing technology, today announced the launch of its next-generation, end-to-end email solution designed to help brands maximize the impact of every email, from content creation to user experience and compliance. As digital competition intensifies, brands are seeking smarter ways to engage users and build trust. EngageLab leverages AI-driven content, inbox preview, and spam detection to deliver a new standard for email marketing performance and user experience. AI-Powered Content Creation for Personalized Engagement EngageLab's integrated AI content engine enables marketing teams to: Effortlessly generate high-conversion email copy tailored to campaign themes and user profiles. Instantly optimize subject lines and visuals to boost open rates. Polish and refine copy with one click, ensuring every message is professional and on-brand. Inbox Preview: Consistent Experience Across All Devices With over 100 major email clients supported, including Gmail, Outlook and Yahoo, EngageLab's Inbox Preview allows brands to simulate the recipient's experience before sending. This ensures that every email, regardless of device or platform, displays as intended, eliminating costly errors and enhancing user trust. A leading Southeast Asian e-commerce platform recently leveraged EngageLab's Inbox Preview to resolve coupon display issues that had previously resulted in lost orders during major sales events. As a result, the company saw an 80% reduction in email-related complaints and a 22% increase in coupon redemption rates during its 2024 campaign. This feature is now available for a free trial via the EngageLab dashboard. Spam Content Detection: Protecting Brand Reputation and Deliverability EngageLab's intelligent spam detection engine automatically scans email content, subject lines, and images for risky keywords, providing real-time optimization suggestions. This proactive approach helps brands avoid spam filters, maximize inbox placement, and maintain compliance. A Unified Solution for Modern Email Marketing By integrating AI content creation, inbox preview, and spam detection, EngageLab delivers a comprehensive, intelligent email solution that enables brands to: Drive smarter, more creative campaigns. Ensure flawless user experience on every device. Strengthen compliance and brand trust. All these features are now available for free trial, giving brands the opportunity to experience EngageLab's innovation and value risk-free. "With EngageLab, brands can transform every email into a benchmark for quality and engagement," said Iris Xiang, Senior Product Manager at EngageLab. "We're committed to helping our clients achieve measurable growth and lasting customer relationships." For more information, to request a demo, or to start your free trial, visit About EngageLabEngageLab is a world-leading AI-powered omnichannel customer engagement solution provider, unites technology and versatility to offer seamless customer interactions and marketing automation across every channel, including Email, AppPush, WebPush, OTP, SMS and WhatsApp Business. It empowers businesses to build lasting relationships and achieve higher conversions and retention. With a strong focus on innovation and performance, EngageLab supports businesses in over 220 countries and regions, delivering more than 1 million messages every second across various more information about EngageLab and its suite of solutions, visit For Media Inquiries:Contact: marketing@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy
Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy

Yahoo

timean hour ago

  • Yahoo

Nuevocor Announces FDA Clearance of IND for NVC-001 for LMNA-Related Dilated Cardiomyopathy

LMNA-related dilated cardiomyopathy (LMNA DCM) is one of the most aggressive forms of DCM, affecting approximately 100,000 individuals in the United States and Europe, who progress rapidly to end-stage heart failure. NVC-001 demonstrated significant benefits, including survival and cardiac function in preclinical models. IND clearance enables initiation of first-in-human, ascending-dose Phase 1/2 clinical trial in early 2026. SINGAPORE and PHILADELPHIA, June 10, 2025 /PRNewswire/ -- Nuevocor, a Singapore-headquartered biotechnology company developing cures for cardiomyopathies driven by aberrant mechanobiology, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NVC-001. NVC-001 is an adeno-associated virus (AAV)-based gene therapy designed to treat LMNA-related dilated cardiomyopathy (LMNA DCM). Nuevocor plans to initiate an open-label, ascending-dose Phase 1/2 clinical trial of NVC-001 in patients with LMNA DCM. "This IND clearance marks a significant milestone in our mission to develop transformative therapies for patients with genetic cardiomyopathies by leveraging unique insights from our proprietary PrOSIA mechanobiology platform," said Dr. Yann Chong Tan, co-founder and CEO of Nuevocor. "NVC-001 is the first disease-modifying therapy for LMNA DCM designed to address the underlying mechanobiological root cause of disease. We look forward to initiating our clinical trial to bring this potentially life-changing therapy to patients." LMNA DCM is a serious genetic heart condition caused by mutations in the LMNA gene, which encodes lamin A/C – a protein essential for maintaining nuclear envelope integrity and regulating gene expression in cardiac cells. Mutations in LMNA lead to a weakening of the heart muscle, arrhythmias, and progression to end-stage heart failure. LMNA DCM is estimated to affect approximately 100,000 patients in the U.S. and Europe, representing a significant unmet medical need. NVC-001 is engineered to address the functional mechanical root cause of disease by reducing aberrant mechanical stress on the nucleus, thereby restoring nuclear envelope integrity. Nuclear envelope disruption is a hallmark of LMNA DCM. In preclinical studies, treatment with NVC-001 demonstrated significant benefits, including survival and cardiac function. The planned Phase 1/2 clinical trial is a first-in-human, 52-week open-label, multicenter, ascending-dose study designed to evaluate the safety, tolerability, and preliminary efficacy of NVC-001 in adult subjects with LMNA-DCM. NVC-001 will be administered as a one-time intravenous infusion to patients in ascending-dose cohorts. About Nuevocor Nuevocor is biotechnology company developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology, headquartered in Singapore with an office in the U.S. and expansion to Europe. Our unique approach, enabled by our proprietary PrOSIA mechanobiology platform, surpasses the limitations of traditional gene replacement therapy – which treats individual gene mutations – to treating defects in shared disease pathways across multiple cardiomyopathies by addressing the functional root cause of disease. Nuevocor is first-in-disease by addressing genetic cardiomyopathies that are not amendable to gene replacement therapy and have no effective treatment options. ( View original content to download multimedia: SOURCE Nuevocor Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Uber taps AI firm Wayve to pilot fully driverless rides in the UK
Uber taps AI firm Wayve to pilot fully driverless rides in the UK

CNBC

timean hour ago

  • CNBC

Uber taps AI firm Wayve to pilot fully driverless rides in the UK

Uber on Tuesday announced it's partnered with self-driving car technology firm Wayve to launch trials of fully autonomous rides in the U.K. The ride-hailing app said the pilot would be the first of its kind for the company, as it allow users to take Uber rides without a safety driver present — a standard of autonomous driving described by the industry as "Level 4." Self-driving vehicles have become a common sight in San Francisco, where Google's autonomous driving venture Waymo offers a commercial ride-hailing service with its driverless cars. However, other global players are racing to roll out so-called "robotaxi" services of their own. Andrew MacDonald, president and chief operating officer of Uber, said the partnership with Wayve would move the company a step closer toward its vision "to make autonomy a safe and reliable option for riders everywhere." "This is a defining moment for UK autonomy," Wayve CEO and co-founder Alex Kendall said in a statement. "With Uber and a global OEM partner, we're preparing to put our AI Driver technology into real service on the streets of London." Uber said it was able to launch the pilot in the U.K. thanks to an "accelerated framework" for self-driving commercial pilots that's being introduced by the U.K.'s Department of Transport. Uber and Wayve said they would work closely with the government and Transport for London — which is the main authority overseeing transport in the U.K. capital — on regulatory approvals and permissions prior to launching the trials. Backed by SoftBank, Wayve is a London-based startup that develops software to enable self-driving vehicles. Its platform uses artificial intelligence to allow cars to assess their surroundings and it's designed to be applicable in any environment. Last year, the U.K. passed its Autonomous Vehicles Act into law, which the government at the time said would pave the way for self-driving vehicles to arrive on British roads by 2026.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store